| Year |
Citation |
Score |
| Low-probability matches (unlikely to be authored by this person) |
| 2010 |
Hainsworth JD, Spigel DR, Clark BL, Shipley D, Thompson DS, Farley C, West-Osterfield K, Lane CM, Cescon T, Bury MJ, Greco FA. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer Journal (Sudbury, Mass.). 16: 70-5. PMID 20164695 DOI: 10.1097/PPO.0b013e3181c6aa89 |
0.081 |
|
| 2010 |
Spigel DR, Hainsworth JD, Gandhi JG, Gian VG, Peyton JD, West-Osterfield K, Clark BL, Vazquez ER, Jones SF, Burris HA, Greco FA. A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 862-6. PMID 20521352 DOI: 10.1097/JTO.0b013e3181d86a4f |
0.055 |
|
| 2019 |
Hainsworth JD, Becker KP, Mekhail T, Chowdhary SA, Eakle JF, Wright D, Langdon RM, Yost KJ, Padula GDA, West-Osterfield K, Scarberry M, Shaifer CA, Shastry M, Burris HA, Shih K. Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II). Journal of Neuro-Oncology. PMID 31392595 DOI: 10.1007/S11060-019-03227-7 |
0.031 |
|
| 2017 |
Zhang Q, West-Osterfield K, Spears E, Li Z, Panaccione A, Hann SR. MB0 and MBI Are Independent and Distinct Transactivation Domains in MYC that Are Essential for Transformation. Genes. 8. PMID 28481271 DOI: 10.3390/Genes8050134 |
0.012 |
|
| Hide low-probability matches. |